Lymphoma Clinical Trials

Showing 1-20 of 20 items
  • A Study of Lenalidomide for Adult Histiocyte Disorders
  • This research study is studying a chemotherapy drug Lenalidomide as a possible treatment for one of three histiocyte disorders: Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD), or histiocytic sarcoma (HS).
  • Diagnoses: Lymphoma
  • Status: Recruiting
  • Pembrolizumab After ASCT for Hodgkin Lymphoma and DLBCL
  • This phase II study is designed to determine the clinical efficacy of PD-1 blockade, using the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475), administered as consolidation therapy after autologous stem cell transplant (ASCT), in patients with relapsed or refractory (R/R) Diffuse Large B Cell Lymphoma (DLBCL) or classical Hodgkin Lymphoma (cHL).
  • Diagnoses: Lymphoma
  • Status: Recruiting
  • Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma
  • Limited stage Hodgkin lymphoma is a highly curable disease, but standard treatment with ABVD chemotherapy and radiation can lead to late risks of secondary cancers, lung injury, heart injury, and others. This trial eliminates radiation therapy and reduces intensity of chemotherapy by incorporating the highly active FDA-approved targeted therapy brentuximab vedotin, an antibody-drug conjugate specifically against the lymphoma cells, combined with the standard chemotherapy drugs Adriamycin and Dacarbazine (AD).
  • Diagnoses: Lymphoma
  • Status: Recruiting
  • A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma
  • The goal of the study is to identify a dose and schedule of CC-486 that can be safely administered with R-CHOP. To evaluate the safety and maximum tolerated dose (MTD) or the maximal administered dose (MAD) of CC-486 in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in subjects with high risk (IPI 3 or more) previously untreated diffuse large B-cell lymphoma (DLBCL) or Grade 3B follicular lymphoma (FL). Also, to determine pharmacokinetics (PK) of CC-486 when administered alone and in combination with R-CHOP and to explore preliminary efficacy of CC-486 plus R-CHOP by 2007 International Working Group (IWG) criteria. Finally, to evaluate the pharmacodynamic (PD) effects of CC-486, to evaluate potential predictive/correlative biomarkers for DLBCL subgroups that are considered important and to explore cytidine deaminase (CDA) activity and polymorphisms.
  • Diagnoses: Lymphoma
  • Status: Recruiting
  • Safety Study of Anti-LAG-3 in CLL, HL, NHL and MM
  • The purpose of this study is to characterize the safety, tolerability, dose limiting toxicities and maximum tolerated dose of BMS-986016 administered to subjects with relapsed or refractory chronic lymphocytic leukemia, lymphomas and Multiple myeloma
  • Diagnoses: Lymphoma
  • Status: Recruiting
  • A Trial of MK-3475 in Participants With Blood Cancers
  • The purpose of this trial is to evaluate the safety, tolerability, and efficacy of MK-3475 in hematologic malignancies (myelodysplastic syndrome [MDS], smoldering multiple myeloma [SMM], Hodgkin lymphoma [HL], and non-Hodgkin lymphoma [NHL]).
  • Diagnoses: Lymphoma
  • Status: Recruiting
  • A Long-term Extension Study of PCI-32765 (Ibrutinib)
  • The purpose of this study is to collect long-term safety and efficacy data for participants treated with PCI-32765 (Ibrutinib) and to provide ongoing access to PCI-32765 for participants who are currently enrolled in PCI-32765 studies that have been completed according to the parent protocol, are actively receiving treatment with PCI-32765, and who continue to benefit from PCI-32765 treatment.
  • Diagnoses: Lymphoma
  • Status: Recruiting
  • Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma
  • This Phase II studyis designed to investigate the antitumor activity in terms of objective response rate (ORR) of tipifarnib in 18 subjects with advanced Peripheral T-Cell Lymphoma (PTCL). The total number of patients could be extended to 30 pending on the degree of response observed at an interim analysis. Tipifarnib will be administered until disease progression then followed approximately every 12 weeks for survival until either death or 12 months after accrual of the last study subject, whichever occurs first.
  • Diagnoses: Lymphoma
  • Status: Recruiting
Showing 1-20 of 20 items
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms